Overview
Bacillus clausii is a Gram-positive, aerobic, spore-forming bacterium that has been used as a pharmaceutical probiotic for decades, most notably as the four-strain Enterogermina formulation (strains O/C, N/R, SIN, and T) marketed by Sanofi. Like Bacillus coagulans, the spore-forming nature of B. clausii provides exceptional stability during storage and survival through gastric acid, making it particularly practical for clinical applications where reliable gut delivery is essential.
The species has accumulated a substantial evidence base for the prevention and treatment of antibiotic-associated diarrhea, restoration of gut microbiota after antibiotic therapy or proton pump inhibitor (PPI) use, and as an adjunct to Helicobacter pylori eradication therapy. Its decades-long safety record across multiple countries provides a level of clinical confidence that few probiotic species can match.
Classification
B. clausii belongs to the family Bacillaceae within the phylum Bacillota (formerly Firmicutes). It is a Gram-positive, rod-shaped, motile, aerobic bacterium that produces heat-resistant endospores. The species is distinguished from other Bacillus probiotics by its intrinsic resistance to several antibiotics, a characteristic that enables it to be co-administered with antibiotic therapy — the primary clinical context in which it is used. The four Enterogermina strains each carry specific antibiotic resistance profiles: O/C (chloramphenicol), N/R (neomycin/rifampicin), SIN (various), and T (tetracycline).
Key Characteristics
A key characteristic of B. clausii is its production of clausin, a lantibiotic antimicrobial peptide with activity against Gram-positive pathogens including Clostridioides difficile and Bacillus cereus. This bacteriocin production, combined with the species' spore-forming capability and antibiotic resistance, creates a unique probiotic profile suited to the challenging environment of the antibiotic-treated gut.
Research has revealed multiple protective mechanisms. The Enterogermina strains may induce human beta defensin 2 and cathelicidin antimicrobial peptides, rescue cell proliferation, reduce necrosis and apoptosis, and increase production of mucin and tight junction proteins. Studies also indicate that B. clausii may significantly counter PPI-induced dysbiosis by increasing butyrate production and restoring levels of beneficial families like Bacteroidaceae and Ruminococcaceae.
Health Significance
The health significance of B. clausii is best established in the context of antibiotic-associated complications. As an adjunct to antibiotic therapy, the Enterogermina formulation has demonstrated significant reductions in diarrhea, nausea, and abdominal pain across multiple clinical trials, with a safety record spanning decades. For pediatric gastroenteritis, the four-strain combination has shown protective effects against rotavirus through multiple immune defense mechanisms.
The species also shows promise for addressing PPI-induced gut dysbiosis, an increasingly recognized clinical concern given the widespread use of proton pump inhibitors. Research using the SHIME gastrointestinal simulation model suggests that B. clausii may help restore healthy microbial balance disrupted by acid suppression therapy. While the intrinsic antibiotic resistance of B. clausii strains is clinically useful, it is important to note that these resistance genes are chromosomally encoded and not considered transferable to other bacteria, maintaining the safety profile of the species.